Who's do­ing deals in the midst of a crip­pling pan­dem­ic? Here are the top 10 play­ers for March

6 months ago
Deals

Biotech ex­ecs warn that the FDA is fum­bling their re­sponse to the Covid-19 open-door promise, de­lay­ing progress

6 months ago
Bioregnum
Regulatory

A small, ob­scure biotech just won big with their IPO. In this mar­ket. Are you kid­ding me?

6 months ago
Bioregnum
IPOs

FDA OKs a tri­al for a new Covid-19 ther­a­py af­ter an un­usu­al pub­lic­i­ty cam­paign touts its po­ten­tial — with help from Rudy Giu­liani

6 months ago
Bioregnum
R&D

The big C: The deal­mak­ers, dol­lars and dis­eases that have trans­formed the Chi­nese bio­phar­ma mar­ket

7 months ago
Venture
Deals

The glob­al top 50 bio­phar­ma com­pa­nies — End­points News style

7 months ago
R&D

'Dra­mat­ic times': How did an $8B surge in NIH grants over five years change re­search on the ground (if at all)?

7 months ago
Discovery
In Focus

The top 100 bio­phar­ma ven­ture in­vestors at the mega­bil­lions deal ta­ble

8 months ago
Venture

The top 10 bio­phar­ma pipeline blowups, set­backs and sna­fus for H2 2019

8 months ago
Bioregnum

Weak pipeline? Why, Sanofi ex­ecs are sud­den­ly over the moon about their prospects

8 months ago
Bioregnum
R&D

The pow­er of prece­dent: How a one-off de­ci­sion by Janet Wood­cock es­tab­lished an un­in­tend­ed fast path­way at the FDA — what will fol­low?

8 months ago
Bioregnum

The FDA un­veils a new reg­u­la­to­ry frame­work to speed along gene ther­a­pies, re­ward­ing the lead­ing play­ers

8 months ago
Bioregnum

Who knew? Der­mi­ra’s board kept watch as its stock price tracked Eli Lil­ly’s se­cret bid­ding on a $1.1B buy­out

8 months ago
Deals

#JPM20 ex­clu­sive: Olivi­er Brandi­court fol­lows the Big Phar­ma CEO path to pri­vate eq­ui­ty, join­ing Black­stone ahead of a mam­moth fund de­but

9 months ago
People
R&D

Watch live: End­points at #JPM20

9 months ago

Just how big is the bio­phar­ma deal­mak­ing world? In 2019 we saw mega­bil­lions in cash change hands, and that's just the tip of the ice­berg

9 months ago
Deals

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

9 months ago
Special
Pharma

Paul Biondi's track record at Bris­tol-My­ers cov­ered bil­lions in deals of every shape and size. Here's the com­plete break­down

10 months ago
R&D

The big drug hunters: No­var­tis’ $28B-plus deal spree makes Vas Narasimhan one of the top deal­mak­ers of our time

11 months ago

Stephen Hahn gets through Sen­ate’s soft­ball job in­ter­view — but most­ly plays dodge­ball on the is­sues fac­ing the FDA

11 months ago
Bioregnum

Eliz­a­beth War­ren pro­pos­es us­ing com­pul­so­ry li­cens­ing, an­titrust ac­tions to break bio­phar­ma’s con­trol of drug pric­ing — and here are the block­busters she’s tar­get­ing first

11 months ago
Bioregnum
Pharma

Alzheimer's break­through? Not so fast — ex­perts poke holes in da­ta un­der­ly­ing Chi­na's sur­prise ap­proval

11 months ago
China
In Focus

As CRISPR hori­zons cloud, a start­up fo­cus­es on the next big thing with pow­er­house po­ten­tial — the RNA edit­ing plat­form

11 months ago
Startups

Worth­less? Short at­tack on Fi­bro­Gen claims their ane­mia drug roxa has a lethal Achilles’ heel — and it’s go­ing down

11 months ago
R&D
Pharma
First page Previous page 123456 Next page Last page